ERIS.NS Profit & Loss
Eris Lifesciences Ltd.
Profit & Loss Balance Sheet Cash Flow
Profit & Loss · 4 years on file
(FY2022-23 to FY2025-26)
· fetched 2026-08-24 01:34
| Line item | FY2022-23 | FY2023-24 | FY2024-25 | FY2025-26 | Source (XBRL element) |
|---|---|---|---|---|---|
| Revenue from Operations | ₹16.85 Bn | ₹20.09 Bn | ₹28.94 Bn | ₹31.29 Bn | RevenueFromOperations |
| Gross Revenue (incl. inter-segment) | N/A | N/A | N/A | N/A | SegmentRevenueFromOperations |
| Other Income | ₹0.11 Bn | ₹0.24 Bn | ₹0.18 Bn | ₹0.08 Bn | OtherIncome |
| Total Income | ₹16.96 Bn | ₹20.33 Bn | ₹29.12 Bn | ₹31.37 Bn | Income |
| Cost of Materials Consumed | ₹1.42 Bn | ₹1.78 Bn | ₹2.76 Bn | ₹3.27 Bn | CostOfMaterialsConsumed |
| Purchases of Stock-in-Trade | ₹2.06 Bn | ₹2.02 Bn | ₹4.73 Bn | ₹4.91 Bn | PurchasesOfStockInTrade |
| Changes in Inventories | ₹0.04 Bn | ₹0.01 Bn | ₹-0.35 Bn | ₹-0.22 Bn | ChangesInInventoriesOfFinishedGoodsWorkInProgressAndStockInTrade |
| Employee Benefit Expense | ₹3.46 Bn | ₹4.04 Bn | ₹5.05 Bn | ₹5.57 Bn | EmployeeBenefitExpense |
| Finance Costs | ₹0.26 Bn | ₹0.85 Bn | ₹2.31 Bn | ₹1.93 Bn | FinanceCosts |
| Depreciation and Amortisation | ₹1.17 Bn | ₹1.83 Bn | ₹3.15 Bn | ₹2.79 Bn | DepreciationDepletionAndAmortisationExpense |
| Other Expenses | ₹4.50 Bn | ₹5.50 Bn | ₹6.57 Bn | ₹6.57 Bn | OtherExpenses |
| Total Expenses | ₹12.92 Bn | ₹16.02 Bn | ₹24.23 Bn | ₹24.81 Bn | Expenses |
| Profit Before Exceptional Items and Tax | ₹4.05 Bn | ₹4.31 Bn | ₹4.89 Bn | ₹6.56 Bn | ProfitBeforeExceptionalItemsAndTax |
| Exceptional Items | ₹0.00 Bn | ₹0.00 Bn | ₹0.00 Bn | ₹-0.17 Bn | ExceptionalItemsBeforeTax |
| Profit Before Tax | ₹4.05 Bn | ₹4.31 Bn | ₹4.89 Bn | ₹6.38 Bn | ProfitBeforeTax |
| Tax Expense | ₹0.30 Bn | ₹0.34 Bn | ₹1.14 Bn | ₹-0.09 Bn | TaxExpense |
| Net Profit (incl. minority interest) | ₹3.74 Bn | ₹3.97 Bn | ₹3.75 Bn | ₹6.48 Bn | ProfitLossForPeriod |
| Net Profit (to shareholders) | ₹3.82 Bn | ₹3.92 Bn | ₹3.52 Bn | ₹6.20 Bn | ProfitOrLossAttributableToOwnersOfParent |
| Basic EPS | ₹28.10 | ₹28.82 | ₹25.85 | ₹45.33 | BasicEarningsLossPerShareFromContinuingAndDiscontinuedOperations |
| Diluted EPS | ₹28.07 | ₹28.79 | ₹25.81 | ₹45.26 | DilutedEarningsLossPerShareFromContinuingAndDiscontinuedOperations |
Every figure above is the exact value of the named XBRL element from ERIS.NS's cached filing for that year — nothing here is estimated or backfilled. A company shows one column per year StockProof actually has data for — never padded with blank years. Rows shown as N/A are genuinely not disclosed under that year's filing format (see peer comparison for how other Healthcare companies compare).